Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic Duct Stenting and Indomethacin for PEP
NCT03643900Completed
- Sponsor
- Hangzhou First People's Hospital
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Randomised trial (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Incidence of Post-ERCP Pancreatitis at 24 hours. Started Aug 2018; status: completed.
Beyond the preview
Go deeper on NCT03643900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643900.